Unusual Volume Noted in Tuesday's ETF: IVE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 18 2025
0mins
Source: NASDAQ.COM
ETF Performance: The iShares S&P 500 Value ETF saw significant trading volume on Tuesday, with Ford Motor and Warner Bros. Discovery showing notable gains.
Top Performers: Medtronic was the best-performing component of the ETF, rising by approximately 5.8%, while Western Digital experienced a decline of about 4.6%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 79.200
Low
102.00
Averages
111.76
High
120.00
Current: 79.200
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Da Vinci System Innovation: Intuitive Surgical's Da Vinci 5 system installations reached 232 in Q1, a 58% increase from 147 a year earlier, demonstrating strong market momentum for the new product and further solidifying the company's market leadership.
- Strong Competitive Moat: With most surgeons trained on the Da Vinci system, hospitals tend to stick with the platform after purchase, significantly reducing the threat from competitors and ensuring Intuitive Surgical's sustained profitability.
- Diverse Revenue Streams: In the latest quarter, revenue from accessories and instruments totaled $1.6 billion, compared to $650 million from system sales, indicating the company's ability to generate high recurring revenue through accessories and service contracts, enhancing financial stability.
- Global Market Expansion: The installed base of Da Vinci systems grew to 11,395, a 12% year-over-year increase, while global procedures rose by 16%, indicating increased hospital reliance on the platform, thereby driving long-term revenue growth for the company.
See More
- Market Leadership: Intuitive Surgical's Da Vinci surgical robot maintains a dominant position in operating rooms globally, with 232 placements of the Da Vinci 5 system in Q1, reflecting a 58% year-over-year increase, which reinforces the company's market position.
- Strong Competitive Moat: Most surgeons trained on the Da Vinci system tend to prefer it, and hospitals are likely to continue using it after making a significant investment, reducing competitive threats and positively impacting the company's earnings outlook.
- Diverse Revenue Streams: In the latest quarter, revenue from accessories and instruments reached $1.6 billion, significantly exceeding the $650 million from system sales, indicating that the company has established a sustainable recurring revenue model that enhances financial stability.
- Expanding Market Share: The installed base of Da Vinci systems has grown to 11,395, a 12% year-over-year increase, with a 16% rise in procedures, indicating increased hospital reliance on the platform and laying a solid foundation for future revenue growth.
See More
- Medical Device Leader: Medtronic boasts a 49-year dividend growth history with a current yield of 3.5%, and despite market fluctuations, its latest report indicates the highest annual revenue growth in a decade, reflecting effective restructuring efforts to enhance profitability.
- Real Estate Investment Trust: Realty Income offers a 5.2% dividend yield and has increased dividends for 31 consecutive years; as the largest net lease REIT, its portfolio spans North America and Europe, maintaining over 96% occupancy during economic downturns, showcasing its stability and reliability.
- Steel Industry Leader: Nucor, recognized as a Dividend King with over 50 consecutive annual hikes, currently has a low yield of 0.9%, yet its modern electric arc steel mills and strong employee relations enable it to perform well amid cyclical fluctuations, making it a solid long-term hold.
- Long-Term Investment Strategy: The author emphasizes a commitment to holding these quality stocks through market volatility, believing that Medtronic, Realty Income, and Nucor are proven successful companies that will continue to grow, making them worthy of attention for long-term investors.
See More
- Healthcare Giant: Medtronic has maintained a dividend increase streak for 49 years, with a current yield of 3.5%, and despite market downturns, it recently reported its highest annual revenue growth in a decade, indicating a successful restructuring and potential for stable dividend growth even in a bear market.
- Real Estate Investment Trust: Realty Income offers a 5.2% dividend yield and has increased its dividend for 31 consecutive years; while not at historical highs, its absolute yield remains attractive, and its occupancy rate never dropped below 96% during the Great Recession, showcasing its reliability amid market fluctuations.
- Steel Industry Leader: Nucor, known for over 50 consecutive years of dividend increases, currently has a low yield of 0.9%, but has only reported one loss in the last four decades, demonstrating resilience in a cyclical industry, making it a potential quality pick for investors during a bear market.
- Long-Term Holding Strategy: The author intends to hold Medtronic, Realty Income, and Nucor through market volatility, believing that these companies' management capabilities and historical performance will enable continued growth in future market conditions, reflecting the value of long-term investing.
See More
- Healthcare Giant's Performance: Medtronic has reported its highest annual revenue growth in a decade, and with a 49-year history of dividend increases and a 3.5% yield, it remains attractive during economic downturns, expected to continue its reliable dividend payouts.
- Stability of REITs: Realty Income, the largest net lease REIT with over 15,500 properties, has increased its dividend for 31 consecutive years, boasting a 5.2% yield and maintaining occupancy above 96% during the Great Recession, demonstrating its reliability in market downturns.
- Steel Industry Leader: Nucor, recognized as a top player in the steel industry, has a low yield of 0.9% but boasts over 50 consecutive years of dividend hikes and strong employee relations, making it a solid long-term hold despite cyclical industry challenges.
- Long-Term Investment Strategy: The author intends to hold Medtronic, Realty Income, and Nucor through market fluctuations, channeling Warren Buffett's investment philosophy to focus on the long-term growth potential of these well-managed companies, regardless of market conditions.
See More
- Market Valuation: Despite increased market volatility, veteran investor Jeremy Grantham highlights that we are in the most expensive market in U.S. history, prompting investors to seek high dividend stocks for income while waiting for asset appreciation, thereby providing a stable cash flow in an uncertain economic environment.
- Dividend Stock Screening: CNBC Pro screened the Vanguard Dividend Appreciation Index Fund ETF and found stocks with dividend yields above 1.5%, where over 55% of analysts rated them as buys, and price targets are at least 20% above current trading prices, indicating strong market confidence in these stocks.
- Abbott Laboratories Performance: Abbott Laboratories offers a 2.7% dividend yield and has fallen nearly 10% in the past three months, yet analysts see a 23% upside potential, with 79% rating it a buy, reflecting its long-term growth potential in the healthcare sector.
- Medtronic's Growth Potential: Medtronic yields 3.6% and has dropped 8% in the last three months, but analysts believe it has a 19% upside potential, and the company's investments in emerging medical technologies are expected to drive future growth, with 64% of analysts rating it a buy.
See More











